REFERENCES
1. Standards of specialized diabetes care. In: I.I. Dedov., M.V. Shestakova, A. Yu. Mayorov (eds). 10th ed. Moscow, 2021. (in Russian)
2. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.A., Isakov M.A. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Sakharniy diabet [Diabetes Mellitus]. 2018; 21 (3): 144-59. DOI: https://doi.org/10.14341/DM9686 (in Russian)
3. Bode B., Garrett V., Messler J., et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020; 14 (4): 813-21. DOI: https://doi.org/10.1177/1932296820924469
4. DeFronzo R.A., Eldor R., Abdul-Ghani M. Pathophysiologic approach to therapy in T2DM. Diabetes Care. 2013; 36 (Suppl 2): S 127-38. DOI: https://doi.org/10.2337/dcS13-2011
5. Dedov I.I., Smirnova O.M., Kononenko I.V. New concepts of glucose-induced insulin secretion in the development of type 2 diabetes: clinical implications. Sakharniy diabet [Diabetes Mellitus]. 2015; 18 (3): 23-31. DOI: https://doi.org/10.14341/DM2015323-31 (in Russian)
6. Yasuda K., Inagaki N., Yamada Y., et al. Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties. Biochem Biophys Res Commun. 1994; 205 (3): 1556-62. DOI: https://doi.org/10.1006/bbrc.1994.2844
7. Zaccardi F., Jacquot E., Cortese V., Tyrer F., Seidu S., Davies M.J., et al. Comparative effectiveness of gliclazide modified release versus sita-gliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22 (12): 2417-26. DOI: https://doi.org/10.1111/dom.14169
8. Maloney A., Rosenstock J., Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019; 105 (5): 1213-23.
9. Al Sifri S., Basiounny A., Echtay A., Al Omari M., et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with si-tagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011; 65: 1132-40.
10. Hassanein M., Al Sifri S., Shaikh S., Abbas Raza S., Akram J., Pranoto A., et al.; on behalf of the DIA-RAMADAN Study Investigators, A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020; 163: 108154. DOI: https://doi.org/10.1016/j.diabres.2020.108154
11. Schernthaner G., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004; 34: 535-42.
12. Matthews D.R. ADVANCE. Diabetes Obes Metab. 2020; 22 (Suppl 2): 3-4. DOI: https://doi.org/10.1111/dom.14014
13. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118-20.
14. Zhou F., Yu T., Du R., Fan G., Liu Y., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10 229): 1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3 Epub 2020 Mar 11.
15. Shestakova M.V., Vikulova O.K., Isakov M.A., Dedov I.I. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the Russian diabetes registry. Problemy endokrinologii [Problems of Endocrinology]. 2020; 66 (1): 35-46. DOI: https://doi.org/10.14341/probl12458 (in Russian)
16. Drucker D.J. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020; 41: 457-70.
17. Hahn K., Ejaz A.A., Kanbay M., Lanaspa M.A. Johnson R.J. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016; 12: 711-2.
18. Stoian A.P., Papanas N., Prazny M., Rizvi A.A., Rizzo M. Incretin-based therapies role in COVID-19 era: evolving insights. J Car-diovasc Pharmacol Ther. 2020; 25 (6): 494-6. DOI: https://doi.org/10.1177/1074248420937868
19. Nauck M.A., Meier J.J. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019; 181: R 211-34.
20. Lukito A.A., Pranata R., Henrina J., Lim M.A., Lawrensia S., Suas-tika K. The Effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020; 14 (6): 2177-83. DOI: https://doi.org/10.1016/j.dsx.2020.11.006 Epub 2020 Nov 11. PMID: 33395778; PMCID: PMC 7657016.
21. Zhao W., Yu S., Zha X., Wang N., Pang Q., Li D., et al. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.03.13.20035436
22. Luo M., Zuo Y., Guo J., Wen X., Kang Y. Continuous glucose monitoring system can improve the quality of glucose control and glucose variability compared with point-of-care measurement in critically ill patients: a randomized controlled trial. Medicine (Baltimore). 2018; 97: e12138.
23. Takahashi T., Shibasaki T., Takahashi H., et al. Antidiabetic sulfonyl-ureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013; 6 (298): ra 94. DOI: https://doi.org/10.1126/scisignal.2004581